JPRN-jRCT2080221162
Unknown
Phase 3
A double-blind confirmatory study for AD-810N (zonisamide) in patients with Parkinson's disease (Phase III)
ConditionsParkinson's disease
Overview
- Phase
- Phase 3
- Enrollment
- 360
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 74age old (—)
- Sex
- All
Inclusion Criteria
- •Patients with Parkinson's disease who meet the following criteria
- •\- Patients who are effective in the treatment of L\-DOPA single\-agent or L\-DOPA/DCI combination of drugs when initiated treatment
- •\- Patients who are taking L\-DOPA/DCI combination of drugs continuously for more than 6 months
- •\- Patients who have developed the wearing\-off phenomenon
Exclusion Criteria
- •\- Patients with epilepsy
- •\- Patients who are taking L\-DOPA single\-agent
- •\- Patients with a history of treatment with zonisamide
Investigators
Similar Trials
Unknown
Phase 2
An Exploratory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies (Phase 2 study)JPRN-jRCT2080221994Dainippon Sumitomo Pharma Co., Ltd.150
Unknown
Phase 3
Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.JPRN-jRCT2080222787Sumitomo Dainippon Pharma Co., Ltd.300
Unknown
Phase 3
Double-blind confirmatory study of AD-5423 (blonanserin) in patients with schizophrenia [Phase 3 study]JPRN-jRCT2080220098Dainippon Sumitomo Pharma Co., Ltd.
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of AD-218Mixed DyslipidemiaNCT05400317Addpharma Inc.520
Active, not recruiting
Phase 1
ADP-A2M4CD8 in advanced cancersadvanced esophageal or esophagogastric junction (EGJ) cancersMedDRA version: 21.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-005802-24-ESAdaptimmune LLC45